Work

Supplementary Table S5 from A Phase 2 Study of the MEK1/2 Inhibitor Luvometinib in Patients with Extracranial Arteriovenous Malformations

Year: 2026

Type: supplementary-materials

Abstract: Best overall response by gene mutation per DSA and MRI assessment (mITT set).

DOI: 10.1158/1078-0432.33253404

Authors: Chen Hua, Zhuli Wu, Xingli Wang, Huilong Liu, Ben Li, Yang Zheng, Xiaoxi Lin

Language: English

Topic: Vascular Malformations Diagnosis and Treatment

Subfield: Clinical Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W7203499779

Cites:

Cited by:

Related to: 10